1
|
Winawer SJ, Zauber AG, Ho MN, O'Brien MJ,
Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond J, Panish JF,
et al: Prevention of colorectal cancer by colonoscopic polypectomy.
The National Polyp Study Workgroup. N Engl J Med. 329:1977–1981.
1993. View Article : Google Scholar : PubMed/NCBI
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
3
|
Bird RP: Observation and quantification of
aberrant crypts in the murine colon treated with a colon
carcinogen: Preliminary findings. Cancer Lett. 37:147–151. 1987.
View Article : Google Scholar : PubMed/NCBI
|
4
|
McLellan EA and Bird RP: Aberrant crypts:
Potential preneoplastic lesions in the murine colon. Cancer Res.
48:6187–6192. 1988.PubMed/NCBI
|
5
|
McLellan EA, Medline A and Bird RP: Dose
response and proliferative characteristics of aberrant crypt foci:
Putative preneoplastic lesions in rat colon. Carcinogenesis.
12:2093–2098. 1991. View Article : Google Scholar : PubMed/NCBI
|
6
|
McLellan EA, Medline A and Bird RP:
Sequential analyses of the growth and morphological characteristics
of aberrant crypt foci: Putative preneoplastic lesions. Cancer Res.
51:5270–5274. 1991.PubMed/NCBI
|
7
|
Pretlow TP, Barrow BJ, Ashton WS,
O'Riordan MA, Pretlow TG, Jurcisek JA and Stellato TA: Aberrant
crypts: Putative preneoplastic foci in human colonic mucosa. Cancer
Res. 51:1564–1567. 1991.PubMed/NCBI
|
8
|
Takayama T, Katsuki S, Takahashi Y, Ohi M,
Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H and Niitsu Y:
Aberrant crypt foci of the colon as precursors of adenoma and
cancer. N Engl J Med. 339:1277–1284. 1998. View Article : Google Scholar : PubMed/NCBI
|
9
|
Adler DG, Gostout CJ, Sorbi D, Burgart LJ,
Wang L and Harmsen WA: Endoscopic identification and quantification
of aberrant crypt foci in the human colon. Gastrointest Endosc.
56:657–662. 2002. View Article : Google Scholar : PubMed/NCBI
|
10
|
Hurlstone DP, Karajeh M, Sanders DS, Drew
SK and Cross SS: Rectal aberrant crypt foci identified using
high-magnification-chromoscopic colonoscopy: Biomarkers for flat
and depressed neoplasia. Am J Gastroentrol. 100:1283–1289. 2005.
View Article : Google Scholar
|
11
|
Seike K, Koda K, Oda K, Kosugi C, Shimizu
K, Nishimura M, Shioiri M, Takano S, Ishikura H and Miyazaki M:
Assessment of rectal aberrant crypt foci by standard chromoscopy
and its predictive value for colonic advanced neoplasms. Am J
Gastroenterol. 101:1362–1369. 2006. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kim J, Ng J, Arozulllah A, Ewing R, Llor
X, Carroll RE and Benya RV: Aberrant crypt focus size predicts
distal polyp histopathology. Cancer Epidemiol Biomarkers Prev.
17:1155–1162. 2008. View Article : Google Scholar : PubMed/NCBI
|
13
|
Rudolph RE, Dominitz JA, Lampe JW, Levy L,
Qu P, Li SS, Lampe PD, Bronner MP and Potter JD: Risk factors for
colorectal cancer in relation to number and size of aberrant crypt
foci in humans. Cancer Epidemiol Biomarkers Prev. 14:605–608. 2005.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Moxon D, Raza M, Kenney R, Ewing R,
Arozullah A, Mason JB and Carroll RE: Relationship of aging and
tobacco use with the development of aberrant crypt foci in a
predominantly African-American population. Clin Gastroenterol
Hepatol. 3:271–278. 2005. View Article : Google Scholar : PubMed/NCBI
|
15
|
Stevens RG, Swede H, Heinen CD, Jablonski
M, Grupka M, Ross B, Parente M, Tirnauer JS, Giardina C, Rajan TV,
et al: Aberrant crypt foci in patients with a positive family
history of sporadic colorectal cancer. Cancer Lett. 248:262–268.
2007. View Article : Google Scholar : PubMed/NCBI
|
16
|
Sakai E, Takahashi H, Kato S, Uchiyama T,
Hosono K, Endo H, Maeda S, Yoneda M, Taguri M and Nakajima A:
Investigation of the prevalence and number of aberrant crypt foci
associated with human colorectal neoplasm. Cancer Epidemiol
Biomaekers Prev Res. 20:1918–1924. 2011. View Article : Google Scholar
|
17
|
Mutch MG, Schoen RE, Fleshman JW, Rall CJ,
Dry S, Seligson D, Charabaty A, Chia D, Umar A, Viner J, et al: A
multicenter study of prevalence and risk factors for aberrant crypt
foci. Clin Gastroenterol Hepatol. 7:568–574. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Cho NL, Redston M, Zauber AG, Carothers
AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM,
Saltzman JR, et al: Aberrant crypt foci in the adenoma prevention
with celecoxib trial. Cancer Prev Res. 1:21–31. 2008. View Article : Google Scholar
|
19
|
Hosono K, Endo H, Takahashi H, Sugiyama M,
Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, et al:
Metformin suppresses colorectal aberrant crypt foci in a short-term
clinical trial. Cancer Prev Res. 3:1077–1083. 2010. View Article : Google Scholar
|
20
|
Takayama T, Nagashima H, Maeda M, Nojiri
S, Hirayama M, Nakano Y, Takahashi Y, Sato Y, Sekikawa H, Mori M,
et al: Randomized double-blind trial of sulindac and etodolac to
eradicate aberrant crypt foci and to prevent sporadic colorectal
polyps. Clin Cancer Res. 17:3803–3811. 2011. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ezuka A, Sakai E, Kawana K, Nagase H,
Kakuta Y, Uchiyama S, Ohkubo H, Higurashi T, Nonaka T, Endo H, et
al: Association between factors associated with colorectal cancer
and rectal aberrant crypt foci in humans. Oncol Lett. 10:3689–3695.
2015.PubMed/NCBI
|
22
|
Ohkubo H, Takahashi H, Yamada E, Sakai E,
Higurashi T, Uchiyama T, Hosono K, Endo H, Taguri M and Nakajima A:
Natural history of human aberrant crypt foci and correlation with
risk factors for colorectal cancer. Oncol Rep. 27:1475–1480.
2012.PubMed/NCBI
|